Fukuoka, Kurume, Japan Clinical Trials

A listing of Fukuoka, Kurume, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 67 clinical trials
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

mirikizumab
Yukinoseibokai St. Mary's Hospital
 (1.0 away) Contact site
  • 1722 views
  • 24 Jul, 2021
  • +880 other locations
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

endoscopy
fistulising crohn's disease
crohn's disease
abdominal pain
ustekinumab
Kurume University Hospital
 (0.6 away) Contact site
  • 792 views
  • 19 Jul, 2021
  • +799 other locations
A Multicenter Randomized Double-Blind Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to …

remission
Kurume University Hospital /ID# 164427
 (0.6 away) Contact site
  • 611 views
  • 01 Aug, 2021
  • +890 other locations
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1) …

alpha fetoprotein
ct scan
hepatitis
pembrolizumab
Kurume University Hospital ( Site 0119)
 (0.6 away) Contact site
  • 136 views
  • 29 Jul, 2021
  • +254 other locations
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy

ct scan
carcinoma
cetuximab
docetaxel
paclitaxel
Kurume University Hospital
 (0.6 away) Contact site
  • 20 views
  • 10 Apr, 2021
  • +43 other locations
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

mirikizumab
plaque psoriasis
Kurume University Hospital
 (0.6 away) Contact site
  • 717 views
  • 27 Jul, 2021
  • +354 other locations
Study of Durvalumab + Tremelimumab Durvalumab and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

cancer chemotherapy
chemoradiotherapy
prophylactic cranial irradiation
limited stage small cell lung cancer
etoposide
Research Site
 (0.6 away) Contact site
  • 268 views
  • 01 Aug, 2021
  • +246 other locations
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage …

epidermal growth factor
tyrosine
stage iv non-small cell lung cancer
epidermal growth factor receptor
lung carcinoma
Kurume University Hospital /ID# 227776
 (0.6 away) Contact site
  • 118 views
  • 01 Aug, 2021
  • +366 other locations
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).

endoscopy
mirikizumab
Yukinoseibokai St. Mary's Hospital
 (1.0 away) Contact site
  • 386 views
  • 26 Jul, 2021
  • +906 other locations
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

This study will assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

epidermal growth factor
growth factor
osimertinib
stage iv non-small cell lung cancer
EGFR
Kurume University Hospital (12889)
 (0.6 away) Contact site
  • 84 views
  • 01 Aug, 2021
  • +174 other locations